<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000600009</article-id>
<article-id pub-id-type="doi">10.7399/fh.13171</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El beneficio del paciente como objetivo de la humanización]]></article-title>
<article-title xml:lang="en"><![CDATA[Patient benefit as a goal of humanization]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Sierra]]></surname>
<given-names><![CDATA[Manuel David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Briceño-Casado]]></surname>
<given-names><![CDATA[María del Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Briz]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Puerto Real Sevicio de Farmacia ]]></institution>
<addr-line><![CDATA[Puerto Real Cádiz]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario de Jerez de la Frontera Sevicio de Farmacia ]]></institution>
<addr-line><![CDATA[Jerez de la Frontera Cádiz]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitari i Politècnic La Fe Sevicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>6</numero>
<fpage>367</fpage>
<lpage>371</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000600009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000600009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000600009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El empoderamiento del paciente supone uno de los principales pilares de la humanización. Por ello, la consideración de las preferencias y expectativas de los pacientes debería ser tenida en cuenta durante el ejercicio de cualquiera de los profesionales de la salud. Mejorar la supervivencia global y la calidad de vida son los deseos principales de los pacientes. De hecho, la reciente aparición de los llamados Patient Reported Outcomes ha supuesto un importante foco para los agentes involucrados en la asistencia sanitaria. El farmacéutico hospitalario especializado en la evaluación de medicamentos es un profesional que evalúa la eficacia, seguridad, adecuación y eficiencia de los tratamientos prescritos por facultativos, y debe basar la toma de decisiones tanto en factores técnicos como en los cuatro principios bioéticos. La correcta aplicación de la práctica clínica basada en la evidencia permite proveer a los pacientes de incrementos de supervivencia y/o calidad de vida, adecuando la conveniencia y costes a la situación actual. Teniendo en cuenta esto, podría decirse que la evaluación de medicamentos supone un fuerte compromiso con la humanización. Por otra parte, las organizaciones que promueven la evaluación y selección de medicamentos rigurosamente se erigen como aliados de los pacientes, ya que repercuten de forma directa en éstos y de forma indirecta en la sociedad. Las agencias reguladoras encargadas de la aprobación y financiación de medicamentos en los sistemas sanitarios protagonizan un papel fundamental en el proceso de humanización de la toma de decisiones clínicas y empoderamiento de pacientes, ya que si aprueban el uso de nuevos medicamentos según datos que no miden la calidad de vida o supervivencia de los pacientes cuando ya existen otras alternativas terapéuticas para estas patologías, indirectamente no estarán dando respuesta a las expectativas de los pacientes y conculcarán los principios bioéticos. Esto puede tener una considerable influencia en la relación beneficio-riesgo de los fármacos, pudiendo tratar a pacientes con esquemas que no aportan beneficio, o incluso podrían perjudicarles. Por tanto, ¿hacia dónde debiera ir orientado el proceso de humanización? Parece razonable que el beneficio del paciente sea el objetivo fundamental del proceso de humanización de la asistencia sanitaria, evidentemente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Patient empowerment is one of the main pillars of humanisation. Therefore, consideration of patients&#8217; preferences and expectations should be taken into account during the practice of any healthcare professional. Improving overall survival and quality of life are the main wishes of patients. Indeed, the recent emergence of Patient Reported Outcomes has become an important focus for healthcare providers. The hospital pharmacist specialised in drug evaluation is a professional who evaluates the efficacy, safety, appropriateness and efficiency of treatments prescribed by physicians, and decision-making must be based on both technical factors and the four principles of bioethics. The correct application of evidence-based clinical practice allows to provide patients with increases in survival and/or quality of life, adapting the convenience and costs to the current situation. With this in mind, it could be said that the evaluation of medicines involves a strong commitment to humanisation. On the other hand, organisations that promote the rigorous evaluation and selection of medicines stand as allies of patients, as they have a direct impact on them and an indirect impact on society. Regulatory agencies in charge of approving and financing medicines in healthcare systems play a key role in the process of humanising clinical decision-making and empowering patients. If these agencies approve the use of new medicines based on data that do not measure quality of life or survival of patients when there are already other therapeutic alternatives for these pathologies, they are indirectly failing to meet patients&#8217; expectations and are infringing bioethical principles. This can have a considerable influence on the benefit-risk ratio of drugs, and patients may be treated with regimens that do not provide benefit, or may even harm them. Therefore, where should the process of humanisation be oriented? It seems reasonable that the benefit of the patient should be the fundamental objective of the process of humanisation of healthcare, evidently.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Paciente]]></kwd>
<kwd lng="es"><![CDATA[Humanización]]></kwd>
<kwd lng="es"><![CDATA[Atención centrada en el paciente]]></kwd>
<kwd lng="es"><![CDATA[Empoderamiento]]></kwd>
<kwd lng="es"><![CDATA[Bioética]]></kwd>
<kwd lng="es"><![CDATA[Medicina basada en la evidencia]]></kwd>
<kwd lng="es"><![CDATA[Evaluación de medicamentos]]></kwd>
<kwd lng="en"><![CDATA[Patient]]></kwd>
<kwd lng="en"><![CDATA[Humanisation]]></kwd>
<kwd lng="en"><![CDATA[Patient-centered care]]></kwd>
<kwd lng="en"><![CDATA[Empowerment]]></kwd>
<kwd lng="en"><![CDATA[Bioethics]]></kwd>
<kwd lng="en"><![CDATA[Evidence-based medicine]]></kwd>
<kwd lng="en"><![CDATA[Drug evaluation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berwick]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Nolan]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The triple aim: care, health, and cost]]></article-title>
<source><![CDATA[Health Aff (Millwood)]]></source>
<year>2008</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>759-69</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herborg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Soendergaard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Froekjaer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fonnesbaek]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jorgensen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hepler]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving drug therapy for patients with asthma--part 1: Patient outcomes]]></article-title>
<source><![CDATA[J Am Pharm Assoc (Wash)]]></source>
<year>2001</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>539-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sit]]></surname>
<given-names><![CDATA[JWH]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Chair]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of an empowerment-based self-management intervention on empowerment level, psychological distress, and quality of life in patients with poorly controlled type 2 diabetes: A randomized controlled trial]]></article-title>
<source><![CDATA[Int J Nurs Stud]]></source>
<year>2021</year>
<volume>116</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubeis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guardians of humanity? The challenges of nursing practice in the digital age]]></article-title>
<source><![CDATA[Nurs Philos]]></source>
<year>2021</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Karschuck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Groeben]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Praus]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Miernik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empowerment for our patients: Innovation in everyday urology]]></article-title>
<source><![CDATA[Urologe A]]></source>
<year>2021</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Van Regenmortel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vanhaecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sermeus]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Van Hecke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient empowerment, patient participation and patient-centeredness in hospital care: A concept analysis based on a literature review]]></article-title>
<source><![CDATA[Patient Educ Couns]]></source>
<year>2016</year>
<volume>99</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1923-39</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bognar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rethinking patient involvement in healthcare priority setting]]></article-title>
<source><![CDATA[Bioethics]]></source>
<year>2020</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>403-11</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pino-Ramírez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empoderamiento, experiencia de vida y asociaciones de pacientes con Síndrome Ehlers-Danlos]]></article-title>
<source><![CDATA[Panamerican Journal of Neuropsychology]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>79-94</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="">
<collab>Asociación de pacientes con EPOC</collab>
<source><![CDATA[Guía para el empoderamiento del paciente con EPOC]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="">
<collab>iSanidad: lo mejor de la Sanidad</collab>
<source><![CDATA[La AEMPS subraya la necesidad de crear un nuevo liderazgo para afrontar los desafíos de la farmacia hospitalaria]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barreda Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo Vicedo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Silveira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García Palomo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía de humanización de la Sociedad Española de Farmacia Hospitalaria (SEFH)]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="">
<collab>Redacción Médica</collab>
<source><![CDATA[Farmacia de La Princesa crea el proyecto de humanización &#8220;Princesa en Casa&#8221;]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="">
<collab>Servicio de Farmacia del Hospital General Universitario Gregorio Marañón</collab>
<source><![CDATA[Programa de Humanización 2020-2023]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mar Gomis]]></surname>
<given-names><![CDATA[Pastor]]></given-names>
</name>
</person-group>
<source><![CDATA[Mhearth, &#8220;La salud móvil&#8221; al servicio de la humanización en el paciente trasplantado. Mesa Redonda Humanizar es Innovar]]></source>
<year>2019</year>
<conf-name><![CDATA[ 64 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria]]></conf-name>
<conf-loc>Sevilla </conf-loc>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laryionava]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Winkler]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients&#8217; preferences in non-curable cancer disease]]></article-title>
<source><![CDATA[Oncol Res Trea]]></source>
<year>2019</year>
<volume>42</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>31-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Costentin]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Aggio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shergill]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colaone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study]]></article-title>
<source><![CDATA[Future Oncol]]></source>
<year>2021</year>
<volume>17</volume>
<numero>32</numero>
<issue>32</issue>
<page-range>4275-87</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gracia Guillén]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las enfermedades raras y la ética]]></article-title>
<source><![CDATA[Eidon: Revista de la fundación de ciencias de la salud]]></source>
<year>2017</year>
<volume>47</volume>
<page-range>57-77</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Cavo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jakubowiak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knop]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>518-28</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoenbeck]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions]]></article-title>
<source><![CDATA[Curr Hematol Malig Rep]]></source>
<year>2021</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>491-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whitebird]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Solberg]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegenfuss]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Asche]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Norton]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Swiontkowski]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Personalized outcomes for hip and knee replacement: the patients point of view]]></article-title>
<source><![CDATA[J Patient Rep Outcomes]]></source>
<year>2021</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taliercio]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Biggs]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kean]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Duffin]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicians&#8217; perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2022</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1719-25</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bladh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ottosson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Karlsson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Klintberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wallerstedt]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs: a randomised controlled trial]]></article-title>
<source><![CDATA[BMJ Qual Saf]]></source>
<year>2011</year>
<volume>20</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>738-46</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Briz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga-Fuentes]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Clopés-Estela]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega-Eslava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alegre-Del Rey]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug evaluation is also a clinical activity]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>45</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Hornillos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Suárez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marín Martínez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[De Miguel Beriain]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nieves Vázquez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioethical Concerns During the COVID-19 Pandemic: What Did Healthcare Ethics Committees and Institutions State in Spain?]]></article-title>
<source><![CDATA[Front Public Health]]></source>
<year>2021</year>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Campen]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Poplazarova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Therasse]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Turik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<collab>Biopharmaceutical Bioethics Working Group</collab>
<article-title xml:lang=""><![CDATA[Considerations for applying bioethics norms to a biopharmaceutical industry setting]]></article-title>
<source><![CDATA[BMC Med Ethics]]></source>
<year>2021</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barreda Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mulet Alberola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González Bermejo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Soler Company]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The reason for having a code of pharmaceutical ethics: Spanish Pharmacists Code of Ethics]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2017</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>401-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beauchamp]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Childress]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Principios de ética biomédica]]></source>
<year>1999</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Masson]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barreda Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bellver Capella]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Del Moral García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz del Campo Lozano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Francés Causape]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[González Bermejo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Código de Ética Farmacéutica]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uyl-de Groot]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Heine]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herold]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Szasz]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Dank]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system]]></article-title>
<source><![CDATA[World J Gastrointest Oncol]]></source>
<year>2021</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1109-20</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="book">
<collab>Organisation for Economic Co-operation and Development</collab>
<source><![CDATA[Tackling Wasteful Spending on Health]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[OECD Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Consumo y Bienestar Social</collab>
<source><![CDATA[Comisión Interministerial de precios de medicamentos y productos sanitarios]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Alegre-Del-Rey]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Puigventós-Latorre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ventayol]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A checklist for critical appraisal of indirect comparisons]]></article-title>
<source><![CDATA[Int J Clin Pract]]></source>
<year>2014</year>
<volume>68</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1181-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil-Sierra]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Fénix-Caballero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel Kader-Martin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga-Fuentes]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Hidalgo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón de la Lastra-Romero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Checklist for clinical applicability of subgroup analysis]]></article-title>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2020</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>530-8</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad del Gobierno de España</collab>
<source><![CDATA[Acuerdos de la reunión de la comisión interministerial de precios de los medicamentos. Sesión 219 de 16 de diciembre de 2021]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="">
<collab>Comunidad española de pacientes con mieloma múltiple</collab>
<source><![CDATA[Falta de equidad en el Tratamiento del Mieloma Múltiple (Carta a la Ministra de Sanidad)]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="">
<source><![CDATA[European Medicines Agency]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="">
<source><![CDATA[U.S. Food and Drug Administration]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="">
<collab>U.S. Food and Drug Administration</collab>
<source><![CDATA[Label of XPOVIO]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="">
<collab>Agencia Europea del Medicamento</collab>
<source><![CDATA[Blenrep® EPAR]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="">
<collab>Agencia Europea del Medicamento</collab>
<source><![CDATA[Lartruvo®]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="">
<collab>National Institute for health and Care Excellence</collab>
<source><![CDATA[Accelerated Access Collaborative]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steenhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zwiers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines]]></article-title>
<source><![CDATA[Ther Innov Regul Sci]]></source>
<year>2021</year>
<volume>55</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>633-42</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Rohrich]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Levels of Evidence and their role in EvidenceBased Medicine]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2011</year>
<volume>128</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>305-10</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spieth]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Kubasch]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Penzlin]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Illigens]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Barlinn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Siepmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized controlled trials - a matter of design]]></article-title>
<source><![CDATA[Neuropsychiatr Dis Treat]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>1341-9</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vanderbeek]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Ventz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cloughesy]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2019</year>
<volume>21</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1239-49</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega Eslava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marín Gil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga Fuentes]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[López-Briz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Puigventós Latorre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<collab>GENESIS-SEFH</collab>
<source><![CDATA[Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Informe de Posicionamiento Terapéutico de tucatinib (Tukysa®) en el tratamiento de pacientes adultos con cáncer de mama HER-2 positivo, localmente avanzado o metastásico]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="">
<source><![CDATA[Informe de Posicionamiento Terapéutico de talazoparib (Talzenna®) en pacientes con cáncer de mama HER-2 negativo con mutaciones BRCA 1/2 en progresión a tratamientos previos]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gotay]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Kawamoto]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Bottomley]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Efficace]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognostic significance of patient-reported outcomes in cancer clinical trials]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2008</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1355-63</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinten]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Coens]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Comte]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sprangers]]></surname>
<given-names><![CDATA[MAG]]></given-names>
</name>
<name>
<surname><![CDATA[Cleeland]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2009</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>865-71</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerdes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bräu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Korge]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mortazawi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wiemers]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Realworld effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial]]></article-title>
<source><![CDATA[J Dermatol]]></source>
<year>2021</year>
<volume>48</volume>
<page-range>1854-62</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hegarty]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Frampton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey-Jones]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dodkins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Realworld outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2021</year>
<volume>155</volume>
<page-range>136-44</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2019</year>
<volume>100</volume>
<numero>Pt A</numero>
<issue>Pt A</issue>
</nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="">
<collab>Junta de Andalucía</collab>
<collab>Consejería de Salud y Familias</collab>
<source><![CDATA[Comisión Central para la Optimización y Armonización Farmacoterapéutica]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soler Company]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barreda Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Editorial: Humanizando la atención farmacéutica desde la Farmacia Hospitalaria]]></article-title>
<source><![CDATA[Rev OFIL ILAPHAR]]></source>
<year>2018</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>287-8</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58.</label><nlm-citation citation-type="">
<collab>Vall d&#8217;Hebron Barcelona Hospital Campus</collab>
<source><![CDATA[Vall d&#8217;Hebron idea cajas con ilustraciones humanizadoras para cubrir los sueros de los pacientes pediátricos]]></source>
<year>2021</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
